A Study of DB-1310 in Advanced/Metastatic Solid Tumors (NCT05785741)
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of California, Davis Comprehensive Cancer Center — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
- Research Site 117 — Coral Gables, Florida
- D&H Cancer Research Center LLC — Margate, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
- BRCR global — Plantation, Florida
- Florida Cancer Specialists — Sarasota, Florida
- BRCR Medical Center Inc. — Tamarac, Florida
- Research Site 111 — Atlanta, Georgia
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- Research site 119 — Florham Park, New Jersey
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center — Cincinnati, Ohio
- Tennessee Oncology, PLLC — Nashville, Tennessee
- NEXT Virginia — Fairfax, Virginia
- Henan Cancer Hospital — Zhengzhou, Henan
- Hunan cancer hospital — Changsha, Hunan
- Jiangsu Province hospital — Nanjing, Jiangsu
- Affiliated Hospital of Jiangnan University — Wuxi, Jiangsu
- The first hospital of Jilin University — Changchun, Jilin
- The First Hospital of China Medical University — Shenyang, Liaoning
- Shanghai Chest Hospital — Shanghai, Shanghai Municipality
- Sichuan Provincial People's Hospital — Chengdu, Sichuan
- Research Site 222 — Chengdu, Sichuan
📞 Contact the Study Coordinator
Phone: (626) 433-3820
Email: tiana.zhao@dualitybiologics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.